Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC

被引：3

作者：

Mazieres, J. ^{[1
]}

Novello, S. ^{[2
]}

De Castro, J. ^{[3
]}

Migliorino, M. R. ^{[4
]}

Helland, A. ^{[5
,6
]}

Dziadziuszko, R. ^{[7
]}

Griesinger, F. ^{[8
]}

Wolf, J. ^{[9
]}

Zeaiter, A. ^{[10
]}

Cardona, A. ^{[10
]}

Balas, B. ^{[10
]}

Karagiannis, T. ^{[11
,12
]}

Chlistalla, M. ^{[10
]}

Smoljanovic, V. ^{[10
]}

Oh, I. ^{[12
]}

机构：

[1] Toulouse Univ Hosp, Toulouse, France

[2] Univ Turin, Dept Oncol, Turin, Italy

[3] Univ Hosp La Paz, Dept Med Oncol, Madrid, Spain

[4] San Camillo Forlanini Hosp, Dept Lung Dis, Rome, Italy

[5] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway

[6] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Oncol, Oslo, Norway

[7] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland

[8] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oncol, Oldenburg, Germany

[9] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[10] F Hoffmann La Roche Ltd, Basel, Switzerland

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Chonnam Natl Univ, Hwasun Hosp, Jeonnam, South Korea

来源：

关键词：

Alectinib; chemotherapy; NSCLC;

D O I：

10.1016/j.jtho.2017.09.667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-013

引用

页码：S1897 / S1897

页数：1